Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Dri Healthcare Trust T.DHT.UN

Alternate Symbol(s):  DHTRF

DRI Healthcare Trust is a Canada-based company engaged in global pharmaceutical royalty monetization. The Company is involved in pharmaceutical royalty monetization and provides capital to inventors, academic institutions and biopharma companies. It acquires more than 25 royalties on 20-plus drugs, including Eylea, Orserdu, Omidria, Spinraza, Stelara, Vonjo, Zejula and Zytiga. Its portfolio includes Empaveli/Syfovre, Eylea I, Eylea II, Ilaris, Natpara, Omidria, Oracea, Orserdu I, Orserdu II, Rydapt, Simponi, Spinraza, Stelara, Vonjo I, Vonjo II, Xenpozyme, Xolair, Zejula, Zytiga, sebetralstat, and others. Its therapeutic areas include hematology, ophthalmology, influenza, endocrinology, dermatology, oncology, neurology, immunology, lysosomal storage disorder, hereditary angioedema, and others. The Company is managed by DRI Capital Inc. Its products are marketed by pharmaceutical companies, including Regeneron, Bayer, Santen; AstraZeneca; Takeda; Galderma Laboratories; and others.


TSX:DHT.UN - Post by User

User Avatar Image
(64)
•••
  • SONOFFERGUSX
Comment by SONOFFERGUSon Sep 09, 2024 1:05pm
66 Views
Post# 36215014

RE:NCIB tapped out...

RE:NCIB tapped out...

NCIB has tons of room, it's the automatic unit purchase plan that is tapped.

I'm surprised they haven't reloaded and run hard, but there's probably a reason.  Perhaps new management comp isn't fully baked yet so they aren't appropriately incentivized to push the unit price.

I continue to think that $15 is the right area by year end.  Hopefully a little more patience will pay off.

Weak hands selling on small volume is not a good indication of value.  We know what we've got here.

FWIW, there was a block trade this morning at $11.53 for 113k shares (or so, I can't see the trade history) through an ATS.  That is supportive of a price closer to $12 assuming a 4% discount for the block.  Dunno if that's the right discount rate ofc.

<< Previous
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities